Currently Viewing
American Cancer Society Updates Breast Screening Guideline
October 20, 2015 – Silas Inman
Survivors, Patients Face Challenges in the Workplace
October 19, 2015 – Kelly Johnson
Kyprolis Continues to Advance in Multiple Myeloma
October 14, 2015 – Silas Inman
'Modern Family's" Eric Stonestreet Puts Spotlight on Cancer Advocacy Groups
October 13, 2015 – Beth Fand Incollingo
Early Data Suggest Promise for Immunotherapies in Lymphomas
October 13, 2015 – Staff Writer
14 Questions About Your Breast Cancer Diagnosis
October 12, 2015 – Jame Abraham
FDA Expands Opdivo Approval in Lung Cancer
October 09, 2015 – Jason M. Broderick
FDA Expands Optune's Glioblastoma Multiforme Indication
October 05, 2015 – Silas Inman
Pairing Radiation Oncology and Palliative Care Leads to Better Outcomes
October 05, 2015 – Andrew J. Roth

American Cancer Society Updates Breast Screening Guideline

The American Cancer Society has updated its breast cancer screening guideline to recommend that woman at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45.
BY Silas Inman
PUBLISHED October 20, 2015
The American Cancer Society (ACS) has updated its breast cancer screening guideline to recommend that women at an average risk of breast cancer should wait to undergo annual screening mammography until they reach the age of 45. Additionally, after the age of 55, the guideline recommends transitioning mammography to every other year.

Prior ACS recommendations, first formulated in 2003, recommended that annual screening should begin at age 40. In the updated guideline, screening for women age 40 to 44 is listed as a personal choice rather than a strong recommendation. Additionally, for women older than the age of 55, annual screening is listed as a choice, rather than a recommendation, in favor of biennial (every other year) exams. The new guideline did not place a maximum age on screening, as long as life expectancy was greater than 10 years.

“The option to screen every two years for women beginning at age 55 is based on the fact that postmenopausal breast cancers tend to develop more slowly,” Kevin Oeffinger, chair of the breast cancer guideline panel and a family physician at Memorial Sloan Kettering Cancer Center, said in a statement. “Because of that, women may choose either to continue annual screening or move to screening every two years beginning at age 55. Breast cancers before menopause tend to grow more rapidly, making screening every year important.”

The guideline was compiled following a systematic review of published literature by a team of four clinicians, two biostatisticians, two epidemiologists, two patient representatives and an economist. After this stage, 26 organizations and 22 expert advisors were allowed to participate in an external review.

In addition to the changes in age for screening mammography, the new guideline recommends against clinical breast examination for breast cancer screening among average risk women of any age. Overall, there was a paucity of data for clinical exams, although, available information suggested an increase in false-positives with the examinations.

“These recommendations are made with the intent of maximizing reductions in breast cancer mortality and years of life saved while being attentive to the need to minimize harms associated with screening,” said Oeffinger. “The benefits, burdens, and judgment about that balance differ depending on a woman’s age, health, values, and preferences. These recommendations recognize and reflect those differences.”

Although the updated ACS guideline represents a delayed start for screening, the guideline still recommends the use of mammography earlier than what has been put forward by the U.S. Preventive Services Task Force (USPSTF). In the USPSTF guideline, screening is recommended every two years for those between the ages of 50 and 74 and is recommended against for those aged 40 to 49.

In addition to mammography, the USPSTF advises against teaching women how to perform breast cancer self-examination. Given an absence of evidence on the efficacy of self-exams, the ACS was unable to formulate a recommendation on this topic. However, the document noted that substantial portions of breast cancers are self-detected.

“Though the evidence shows that there are some benefits from mammography screening starting at age 40, those benefits more clearly outweigh the harms from age 45 onward," Elizabeth "Terry" Fontham, founding Dean of the School of Public Health at LSU Health Sciences Center in New Orleans and chair of the ACS Guideline Development Group, said in a statement. "Still, some women will choose to begin screening between age 40 and 44, both because they are concerned about their risk of breast cancer, either in general or because they are at higher risk, and are less concerned about the chances of experiencing a false positive findings. Those women should have the opportunity to start screening at 40 if they choose.”

The only changes made to the ACS guideline were for those at "average" risk, a point that was reinforced by Deanna Attai on Twitter.

Physicians need to do a risk assessment for every patient, Attai tweeted, and pay attention to lifestyle factors that can decrease risk.

Pat W. Whitworth, a breast cancer surgeon at Saint Thomas Health in Nashville, Tenn., reinforced Attai’s point, tweeting that "fewer mammograms" is too general and that “know your risk” is better advice.

For women at high risk for developing breast cancer, an MRI and mammogram is still recommended annually by the ACS. However, a main area of contention on this point is that many women are not unaware of their level of risk, according to the organization Bright Pink, which is focused on prevention and early detection of breast and ovarian cancer in young women.

In their guidelines, Bright Pink continues to recommend annual screening for women at average risk starting at age 40. Additionally, the group continues to support annual clinical breast exams. The group also emphasized the importance of making an informed decision and provided a tool for assessing risk (www.assessyourrisk.org).

The ACS guidelines could only make things more murky, according to Therese Bevers, medical director, Cancer Prevention Center, The University of Texas MD Anderson Cancer Center.

“This is one more set of recommendations that will be confusing to women and their primary care providers,” Bevers said. “Women are going to have questions and their providers may not know how to address them.”
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In